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platform as a biosensor system for neurotoxicant screening and for neuroelectrophysiological studies formultiple
purposes. This paper reports some of our results, which characterize the biosensor pharmacologically. Dose-re-
sponse experiments were conducted using NMDA receptor antagonist AP5 and GABAA receptor agonist musimol
(MUS). The chick FBN biosensor (C-FBN-biosensor) responds to the two agents in a pattern similar to that of ro-
dent counterparts; the estimated EC50s (the effective concentration that causes 50% inhibition of themaximal ef-
fect) are 2.3 μM and 0.25 μM, respectively. Intercultural and intracultural reproducibility and long-term
reusability of the C-FBN-biosensor are addressed and discussed. A phenomenon of sensitization of the biosensor
that accompanies intracultural reproducibility in paired dose-response experiments for the same agent (AP5 or
MUS) is reported. The potential application of the C-FBN-biosensor as an alternative to rodent biosensors in
shared sensing domains (NMDA receptor and GABAA receptor) is suggested.
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Dissociated animal neurons are able to form a neuronal network
within a couple of days after being plated on a microelectrode array
(MEA) with adequate density [6,10,11]. The developing neuronal net-
work spikes spontaneously. An MEA can trace this spontaneous spiking
activity (SSA), which is actually an extracellular record of action poten-
tials, from the neuronal network cultured on the MEA surface. SSA is
subject to various physical and/or chemical changes in the environment,
including changes in temperature, osmolarity, andpHof the cultureme-
dium [19]; mechanical disturbances [3,9]; and the presence of neuroac-
tive or neurotoxic agents [17]. These environmental changes could
cause a change in the rate of SSA and its ﬁring patterns. For this reason,
coupling animal neuron culturewithMEA technology forms a biosensor
system. An MEA-based neuron biosensor is a sensitive functional plat-
form that enables a broad spectrum of research related to the ﬁelds of
electrophysiology, neuroscience, pharmacology, neurotoxicology, biolo-
gy, etc. Its value for rapid, sensitive assessment of functional neurotox-
icity has drawn increasing attention in recent decades [6].
The most widely investigated and used neuron sources for develop-
ment of MEA-based neuron biosensor are rodent cortex, hippocampus,. This is an open access article underand spinal cord [6]. However, the increasing chemical pollutants in our
environment would require millions of animals to screen for
neurotoxicants [1,4], making rodent-sourced neurons prohibitively ex-
pensive in both time andmoney. The technology to generate human-in-
duced pluripotent stem cells (hiPSCs) from mature human cell sources
[23] has great potential for providing a large supply of human neurons
for neurotoxin assessment [21]. However, there are many challenges
and costs associated with ensuring a consistent supply of useful hiPSCs,
particularly regarding reprogramming efﬁciency, differentiation repro-
ducibility, and quality control [21]. Recent and anticipated advances
are expected to overcome these issues.
Meanwhile, the ﬁndings of Dugas-Ford et al. [2]) resolvedmore than
a half century of debate about whether cell-type homologies of the
mammalian neocortex exist in the brains of birds. The group showed
that neocortical cell-type homologies (in particular, the layer IV input
neurons and the layer V neuronal output of mammalian neocortex)
are conserved from reptiles to mammals. These cells are organized
into very different architectures in different species, forming cortical
areas in reptiles, nuclei in birds, and cortical layers in mammals. Based
on these ﬁndings, we hypothesize that despite dramatically different
anatomical architectures betweenmammals and birds, if cortical tissues
from the two species were dissociated and their neurons were cultured
on MEAs, they would form in vitro neuronal networks that would ex-
hibit some functional similarities due to the presence of the same
types of input and output cells.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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MEA-based neuron biosensors in multiple research ﬁelds, we investi-
gated a rarely used, abundant, economical, easily dissected cortical neu-
ron source, chick forebrain. In an effort to develop a chick forebrain
neuron (FBN) biosensor on an MEA that is cost-effective, we accom-
plished the following: 1) assembled the chick FBN biosensor (C-FBN-
biosensor) by establishing a long-term, stable chick FBN culture (C-
FBN-C) on an MEA and characterized it morphologically, functionally,
and developmentally [10,11]; and 2) tested the C-FBN-biosensor by ad-
ministering severalwell-known classic neuroactive agents and studying
how the sensor responded to these pharmacological interventions, com-
pared our results with reports on rodent counterparts in the literature,
and reported preliminary data in a dissertation study [9]. These classic
neuroactive agents included N-methyl-D-aspartate (NMDA), a prototype
agonist of glutamate NMDA receptor; bicuculline (BIC), a speciﬁc GABAA
receptor blocker;magnesium ion (Mg2+), a speciﬁc glutamateNMDA re-
ceptor blocker; tetrodotoxin (TTX), a speciﬁc voltage-gated Na+ channel
blocker; verapamil (VER), a speciﬁc voltage-gated L-type Ca2+ channel
blocker; (2R)-amino-5-phosphonopentanoate (AP5), a speciﬁc gluta-
mate NMDA receptor antagonist; and musimol (MUS), a speciﬁc GABAA
receptor agonist. Among these seven agents, results from AP5 and MUS
are reported here with more detailed analysis. The agent-speciﬁc dose-
response curves for the two agents were obtained, and values of their
EC50 (the effective concentration that causes 50% inhibition of the maxi-
mal effect) were estimated and compared with rodent counterparts;
the intraculture reproducibility of the C-FBN-biosensor was addressed,
and a phenomenon of biosensor sensitization that accompanied the
intraculture reproducibility was reported; and the long-term reusability
of the C-FBN-biosensor was demonstrated. Interculture reproducibility
is discussed.
Unlike hiPSCs, which are cell-type speciﬁc, a C-FBN-C is a mix of dis-
sociated chick forebrain tissues mainly containing cortical neurons and
glial cells and thus is considered native cortical tissue-speciﬁc. Hence, a
biosensor made of C-FBN-C is ﬁrst useful in its own right. It is unique in
the abundance of its source of neurons, ease of forebrain dissection,
cost-effectiveness, and effectiveness in the experiments we conducted.
The terms C-FBN-C and C-FBN-biosensor are used interchangeably in
this paper, with the former focusing on the culture and the latter focus-
ing on its biosensing function.
2. Materials and methods
2.1. Cell culture
MEA preparation, chick forebrain dissection, and dissociation
were the same as described in detail in our previous paper [10]. In
brief, sterilizedMEA chips (MCSMEA-S1-GR, 200/30ir-Ti with inter-
nal ground, MCS GmbH, Reutlingen, Germany) were activated using
low oxygen plasma treatment (PDC-32G, Harrick) for 2–3min. After
surface activation, the chips were immediately coated with 0.05%
polyethylenimine (PEI, P3143, Sigma) at 37 °C overnight. White
Leghorn chick forebrains (Embryonic Day 8, 9, or 10 (E8–E10))
were dissected according to Heidemann et al. [5]). Forebrain cells
were then trypsinized (0.25% trypsin, T4049, Sigma) for 5–7 min
at 37 °C before undergoing a few gentle titrations. The trypsin effect
was deactivated by the addition of serum-containing medium, and
the cell suspension was centrifuged at 1000 rpm for 5 min. Cell pel-
lets were washed once again using serum-free Medium 199 (M199,
M4530, Sigma) supplemented with 2% B27 (17504-044, Gibco) and
1% antibiotic/antimycotic (15240-062, Gibco) and re-suspended in
the same medium for plating on MEA chips.
In contrast to our previous method in which dissociated forebrain
cells were plated evenly on the whole area of an MEA chip with an
inner diameter of 20 mm [10], in this paper, a modiﬁed plating method
was used to produce a culture in the center of anMEA surfacewith a di-
ameter of 8 mm, which dramatically reduced the frequency of mediumchange for long-termmaintenance of a culture. To produce an 8-mmdi-
ameter culture, some leftover bits (about 2 mm thick) of polydimethyl-
siloxane (PDMS)were obtained from amicrofabrication. Holeswere cut
in these PDMSmembranes using a Harris Uni-Core™with 8-mm diam-
eter (Harris US Pat. No. 7093508). A PDMS ring with the desired diam-
eter was then cut using a razor blade and autoclaved. Prior to plating
cells, the PEI used to coat the MEA chips was removed, and the chips
were washed 4 times using deionized water and dried in a cell culture
hood. This drying processwas brief: If too long, itmay reduce the hydro-
philicity that results from surface activation and PEI coating and thus
prevent cells from attaching to theMEA surface. When theMEA surface
was dry, a PDMS ringwas placed in its center (Fig. 1A). Any air between
theMEA surface and the PDMS ringwas removed by gently pressing the
ring using sterilized forceps. Cell suspension was plated within the area
restricted by the PDMS ring (Fig. 1B) at a density of 2000 cells/mm2.
After plating cells as shown in Fig. 1B, the MEA chip was covered with
a Teﬂon® lid (ALAMEA-MEM5, ALA Scientiﬁc) and kept in a regular
cell culture incubator for about 45 min. After 45 min, when most cells
had precipitated to the MEA surface and attached to it, the PDMS
ring was gently removed using a sterilized forceps and 1000 μl
ﬁrst-day culture medium (serum-free M199 used for cell plating)
was gently placed on the MEA chip. The MEA chips with Teﬂon
lids were placed in 100 mm petri dishes and held in a regular incu-
bator (37 °C, 5% CO2, and 95% humidity). The signals of spontaneous
spiking activity (SSA) from cultured neuronal networks are very
sensitive to osmotic ﬂuctuation, and the Teﬂon lid, which is perme-
able to gases but not to water or bacteria [19], helps minimize os-
motic ﬂuctuation in the culture medium between medium
changes. One day after cell plating, the medium was changed to
Neurobasal® medium (NB, 21103-049, Gibco) supplemented with
1% GluMax (35050-061, Gibco), 2% B27 (17504-044, Gibco), 2%
fetal bovine serum (FBS, Sigma), and 1% antibiotic/antimycotic
(15240-062, Gibco) and kept in the same incubator. Fig. 1C shows
a culture at 66 DIV plated in this modiﬁed way using the 8-mm
PDMS ring.
During the ﬁrst three weeks, half of the medium in each MEA chip
was changed once a week. After three weeks cultures were transferred
to a cell culture incubator with the same oxygen supply and humidity,
butwith reduced CO2 supply (0.1%), andmediumwas partially changed
once or twiceweekly. No glial cell proliferation inhibitor was used; glial
cells were co-cultured naturally with FBNs.2.2. MEA recording and data analysis
SSA signals were recorded using MEAs, ampliﬁed using an MCS
1060-INV ampliﬁer (MCS GmbH, Reutlingen, Germany), and col-
lected using MC_Rack software (Version 4.3.0, MCS GmbH, Reut-
lingen, Germany) at a 25 kHz sampling rate. MC_Rack extracted
spike information simultaneously. A threshold of −7 times the
standard deviation (SD) of the mean noise amplitude was set for
spike detection in this study. Bursts were deﬁned using the three
criteria described in our previous papers [10,11] and detected
using NeuroMEA, a MatLab-based program we developed.
NeuroMEA also output many other parameters of SSA (such as
burst duration, interburst interval, percent of spikes within bursts,
interspike interval within bursts, and so on) and created raster
plots that showed the time sequence of the spike for each active
channel during a designated period of time. An active channel was
deﬁned as having ﬁve or more spikes per minute.
SSA signals from C-FBN-Cs were monitored frequently (often every
other day) during the ﬁrst three weeks of development. After three
weeks, the responsiveness of C-FBN-Cs to selected classic neuroactive
agents was tested using a series of dose-response experiments. C-FBN-
Cs that had eleven ormore active channelswere used for dose-response
experiments.
Fig. 1.Modiﬁed cell platingmethod using a PDMS ringwith desired diameter to restrict the area of cell culture. A: An 8-mmdiameter autoclaved PDMS ring in the center of anMEA; B: the
cell suspension was restricted to the PDMS ring; and C: a C-FBN-culture plated using this plating method at 66 DIV.
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There are two major categories of neurons in a cortical structure:
projection neurons and inter neurons [7,8]. Projection neurons are
also called pyramidal cells. Their axons form long bundles of nerve tracts
projecting to other (often remote) functional regions of the brain or spi-
nal cord. Pyramidal cells use glutamate as a neurotransmitter. Activa-
tion of glutamate receptors excites the target neurons. In contrast, the
short axons of inter neurons do not leave the functional region where
they are located. Inter neurons are responsible for regulating and syn-
chronizing the ﬁring activities of projection neurons locally in a particu-
lar cortical functional region. Most inter neurons use gamma-
aminobutyric acid (GABA) as their neurotransmitter, and the activation
of GABAergic receptors inhibits the target neurons.
AP5 is a speciﬁc antagonist of glutamate N-methyl-D-aspartate
(NMDA) receptor [15]. When this receptor is blocked by AP5, the excit-
atory postsynaptic potentials (EPSPs) caused by the natural neurotrans-
mitter glutamate are blocked, and there is little-or-no chance for the
postsynaptic neurons to ﬁre action potentials. If the rate of SSA ﬁring
is reduced or completely blocked in the presence of AP5 in culture me-
dium, the glutamate NMDA receptor is expressed in C-FBN-C and
functioning.
MUS is a speciﬁc agonist of GABAA receptor [16]. Since the activation
of the GABAA receptor causes inhibitory postsynaptic potentials (IPSPs),
the activation of this receptor has an inhibitory effect on the postsynap-
tic neurons. If this receptor is expressed and functions in C-FBN-C in the
presence ofMUS in culturemedium, a reduction in or blocking of theﬁr-
ing rate of SSA would be expected.2.4. Dose-response experiment
To knowwhether and how the SSA signals from C-FBN-C respond to
AP5 andMUS, a dose-response curvewas obtained for each agent. Stock
solutions of both agents were made using phosphate buffered saline
(PBS). To determine an appropriate dose range for dose-response ex-
periments, log10[dose] ranges used for rodent counterparts were
referenced.
Prior to initial dose administration, a 30-minute recording of SSA sig-
nals was performed to obtain baseline reference activity. An initial dose
was administered by gently aspirating 90 μl medium from an MEA,
mixing it with a dose of agent (less than 10 μl), then gently sending
the mixture back to the MEA and gently rocking it to ensure a fast,
even distribution of the added dose. SSA signal recording was started
after dose administration and lasted 30 min. Subsequent doses were
added in the same way accumulatively, with 30 min of recording after
each dose administration. To avoid any perturbation of SSA signals
due to dose administration, the last 10min of each 30-minute recording
was used to evaluate the effect of each agent. Immediately after the 30-minute ﬁnal dose treatment, the culture was washed three times using
fresh medium to remove the neuroactive agent and then recorded for
60 min to trace signal recovery. SSA from most C-FBN-Cs recovered
within a 10 to 30 min period after the agent was washed out. Data
from C-FBN-Cs that recovered slowly (more than 30 min) were not
used in this paper.
2.5. Dose-response data process using NeuroMEA
Data obtained from each dose-response experiment was processed
using NeuroMEA to plot an initial dose(x)-response(y) curve. The
starting point of the curve was the mean burst rate (MBR) of the base-
line value averaged from all active channels from one culture. This base-
line value was the reference used as a control when no dose was
administered. This control value of MBR was set at 1 (100%) on the y-
axis. TheMBR at each dosewas calculated in the sameway andwas nor-
malized to be a percentage of the control value.
Repeated and reproducible dose-response experiments were done
for each agent on different cultures, which generated a group of initial
plots for an agent. GraphPad Prism 5 was used to produce a ﬁnal
dose-response curve that is a combination of the group of initial plots
(curve ﬁtting).
2.6. Sigmoidal curve ﬁtting using GraphPad prism 5
Biologically based dose-response models typically exhibit a sigmoi-
dal shape when the response (on the y-axis) is plotted against the log-
arithm of the doses (on the x-axis). Each of the selected classic
neuroactive agents in this paper has its own agent-speciﬁc patterns of
sigmoidal curves when applied to rodent cortical neuron networks
[14,17,18,20]. We also used the logarithm of the doses (log10[dose]) to
ﬁt the initial curve plots by NeuroMEA to sigmoidal curves. Sigmoid
curve ﬁtting is based on the Hill equation [17,25]:
Y ¼ ySTART þ yEND−ySTARTð Þ
1þ 10 log EC50ð Þ− log Xð Þ½ HC
 
where y is the observed value of a response, ySTART is the highest ob-
served value, yEND is the lowest observed value at the highest dose,
EC50 is the effective concentration that causes 50% of maximal inhibi-
tion, and HC is the Hill coefﬁcient (the slope at the inﬂection point of
the curve, the largest absolute value of the slope of the curve). The larger
the absolute value of HC, the steeper the approach to the inﬂection point
[17,25]. Using this model, GraphPad Prism 5 was used for the sigmoidal
curve ﬁtting and estimation of the EC50 value for selected neuroactive
agents.
Fig. 2.Dose-response curve ﬁtting for AP5. A: A ﬁnal representative dose-response curve ﬁtted from the four individual dose-response experiments shown in B (Y=mean± SE, n=190
total active channels from 4 cultures); B: Four initial individual dose-response curves from four individual dose-response experiments conducted on four different cultures.
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3.1. Dose-response curve ﬁtting for AP5 and MUS
Fig. 2 and Fig. 3 show the curve ﬁttings for AP5 and MUS,
respectively.
We consider that the ﬁtted curves for the two agents administered
to the C-FBN-Cs (Fig. 2A and Fig. 3A) show representative patterns of
the dose-response relationship (agent-speciﬁc pattern of sigmoidal
dose-response curve). The two ﬁgures present the responsive dose
range used, initial dose-response curves of each individual dose-re-
sponse experiment, variations among these initial dose-response
curves, and a ﬁnal representative dose-response curve ﬁtted based on
the individual dose-response curves by GraphPad Prism 5 for each
agent. These two ﬁgures indicate that the glutamate NMDA receptors
and GABAA receptors are expressed in C-FBN-Cs and respond to AP5
and MUS in a predictable, dose-dependent way.
3.2. An initial comparison between C-FBN-Cs and rodent counterparts in
SSA responsiveness to AP5 and MUS
Since the targeted receptors of AP5 and MUS were both expressed
and function in C-FBN-Cs, the purpose of this comparison is to explore
the possibility and the applicability of using C-FBN-C as an alternative
biosensor to rodent counterparts for screening neurotoxicants in shared
sensing domains (i.e., shared receptors or ion channels) on the neededFig. 3.Dose-response curve ﬁtting forMUS. A: A ﬁnal representative dose-response curve ﬁtted
total active channels from 4 cultures); B: Four initial individual dose-response curves from fouscale and at less cost than rodent biosensors (millions of rodents vs. mil-
lions of eggs). To compare the SSA responsiveness between the two spe-
cies, the following three aspects should be considered: 1) the
logarithmic dose range within which a biosensor is reactive to an
agent; 2) the EC50; and 3) the Hill coefﬁcient (the slope at the inﬂection
point of the curve). The dose ranges were the same or almost the same
as the dose ranges we referenced and followed for rodent counterparts.
Regarding the Hill coefﬁcient, 1) it was less frequently reported than
EC50 in rodent-neuron biosensor research, and 2) we found that the
Hill coefﬁcient varied greatly when a broad logarithmic dose range
was used to estimate it. For these reasons, values of EC50 only are pre-
sented in Table 1 for comparison.
It should be noted that among researchers, experimental settings
and animals (chick, rat, and mouse) differed; different (but correlated)
variables represented the mean ﬁring rate in dose-response experi-
ments. However, the values of the estimated EC50 for these agents
were close in terms of the spread of logarithmic dose ranges used in
the experiments. For this reason, this initial comparison suggests that
in the two shared sensing domains (NMDA receptor and GABAA recep-
tor), C-FBN-Cs respond to their ligands in a similar dose-response pat-
tern, with certain differences in the potency of the two agents as
indicated by the comparison of the values of EC50 in Table 1.
For an accurate comparison of the potency of AP5 andMUS between
the two species, 1) future dose-response experiments should be con-
ducted with speciﬁc focus on the linear segment (the middle segment)
of the sigmoid curves within a much narrower dose range than thefrom the four individual dose-response experiments shown in B (Y=mean± SE, n=159
r individual dose-response experiments conducted on four different cultures.
Table 1
A comparison of EC50 between C-FBN-biosensor and rodent counterparts.
Agent Chick Rodent
EC50a (μM) EC50b (μM) Animal Neuron Reference
AP5 2.3 18 Rats Cortical Otto et al. [24])
MUS 0.25 0.16–0.42c
0.03–0.05d
Rats and mice rats Cortical Novelino et al. [23])
Scelfo et al. [26])
a Mean burst rate (MBR) was used as the mean ﬁring rate (the dependent variable) in dose-response experiments.
b Mean spike rate (MSR) was used as the mean ﬁring rate (the dependent variable) in dose-response experiments.
c The range of EC50 of MUS from six different labs in an interlaboratory reproducibility study.
d The range of EC50 of MUS from one lab using different mathematical models.
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into this narrower dose range to study the dose-response relationship;
and 3) dose-response experiments for the two species need to be con-
ducted in the same experimental setting by the same researcher(s).
The EC50 obtained in this way will better estimate the differences in
the potencies of the two agents between the two species; Hill coefﬁ-
cients will also be less variable and become comparable in this context.
Other differences between the two species remain unknown.3.3. Intraculture reproducibility and sensitization of the biosensor
Since the inhibitory effects of AP5 andMUS on SSA are both immedi-
ate and reversible, and C-FBN-Cs can bemaintainedwith functional sta-
bility for several months [10], theoretically, as long as there is no defect
or other problem in their receptors or with the cultures, similar patterns
of dose-response curve for a particular agent should be reproducible in
the same C-FBN-C (intraculture reproducibility). We observed this pre-
dicted intraculture reproducibility (Fig. 4). Moreover, when a similar
pattern of dose-response relationship was reproduced in paired dose-
experiments in the same culture with a 4-to-6-day interexperiment in-
terval, it was accompanied by a leftward shift of the second curve. This
left-forward shift occurred not only for AP5 and MUS, it was also ob-
served with other neuroactive agents in our experiments and was
quite consistent. Fig. 3 shows examples of the leftward shift of the
dose-response curves for AP5 (Fig. 4A) and MUS (Fig. 4B) respectively.
The phenomenon of the leftward shift indicates that when the same
agent was administered to the culture the second time, fewer doses
were needed to produce an effect of equalmagnitude, suggesting a sen-
sitization of the C-FBN-biosensor to the same agent it encountered 4 to
6 days ago. Fig. 4, A and B, show that the leftward shifts of the second
curves are less than 10 μM in general. We do not know whether or
not this difference is signiﬁcant as ameaningful sensitization. It is possi-
ble that rodent counterparts may also be sensitized by paired use of anFig. 4. Intraculture reproducibility and sensitization of C-FBN-biosensor to AP5 (A) andMUS (B)
Two (purple)with a 4-day interexperiment interval. Solid lines show the initial dose-response c
B: MUS dose-response curves conducted on two cultures in the same way as on AP5 are showagent, but we have not seen such a report. In the research area of drug
abuse, sensitization is a mechanism underlying drug addiction that
may take place at various levels of an organism, such as the behavioral
level or receptor level [22,24]. Although the mechanisms of sensitiza-
tion remain poorly understood, at the receptor level it is likely related
to long-term potentiation (LTP). LTP is a mechanism underlying synap-
tic plasticity, which is the ability of chemical synapses to change their
strength [13]. More experiments need to be done to better characterize
the phenomenon and to see how long it lasts, whether it occurs with
longer interexperiment intervals, or whether it still occurs after admin-
istration of an agentmore than three times. In terms of C-FBN-biosensor
development, sensitization seems a desirable property because it in-
creases the biosensor's sensitivity. It should be noted that the initial
curves used for curve ﬁtting in Figs. 1 and 2 were all curves obtained
when an agent was ﬁrst administered to the culture.3.4. Long-term intraculture reusability
Table 2 shows the age (days in vitro, DIV) of each C-FBN-C used for
experiments described in Figs. 2 and 3, and the number of active chan-
nels (active channel count, ACC) for each C-FBN-C on the day the dose-
response experiment was conducted.
The range of ages of C-FBN-Cs used in this paper varied widely, from
34 DIV to 112 DIV (Table 2). For all C-FBN-Cs after each dose-response
experiment, an agent was washed out immediately, and the SSA was
allowed to recover. If the SSA from a culture failed to recover or recov-
ered slowly (longer than 30 min), its dose-response data were not
used; and the culture was discarded. If the SSA recovered within
30 min, the culture was reused within at least 4 days after the previous
use and a different agent was administered, such as Mg2+, TTX, VER,
NMDA, or BIC. Table 2 reﬂects the long-term functional stability and re-
usability of C-FBN-C as a useful novel biosensor. Although the neuroac-
tive agents we used have immediate and reversible effects on SSA, and. A: Paired AP5 dose-response curveswere obtained from Culture One (green) and Culture
urves, and dashed lines show the second curves,which shifted to the left of the initial ones.
n in A.
Table 2
The ages (days in vitro, DIV) of each C-FBN-C used for Figs. 1 and 2 and the active channel count (ACC, the number of active channels) of each sensor on the day of the dose-response
experiment.
AP5 DIV ACC ACC%* MUS DIV ACC ACC%a
Culture_1 64 51 86.4% Culture_1 96 56 95.0%
Culture_2 37 37 62.7% Culture_2 112 48 81.4%
Culture_3 93 43 72.9% Culture_3 43 38 64.4%
Culture_4 34 59 100.0% Culture_4 36 17 28.8%
Total ACC: 190 159
a ACC%: percent of ACC in total channel count of 59 (the total count of microelectrodes for an MEA used in this paper is 60; 59 are measuring and 1 is the reference).
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different receptors or ion channels in a culture were activated or
blocked for different time ranges.We do not knowwhether a previously
used agentmight have any residual effects that are undetectable within
the scale of our measurement. Likewise, we do not know whether such
an agent could cause anyup- or down-regulation of any receptors or po-
tentiate or reduce the effects of the agent used subsequently.
Potentially, all these elements could have increased the variations of
the dose-response experiments, as shown in Fig. 2B and Fig. 3B. In con-
sideration of this and in combination with our results with Mg2+, TTX,
and VER ([12], in review), C-FBN-biosensors still demonstrated remark-
able long-term intraculture reusability. In addition, Table 2 also shows a
high ACC% inmost C-FBN-Cs, reﬂecting that the C-FBN-Cswere well de-
veloped in their environment. The longevity, denser distribution of ac-
tive channels, and characterizable responsiveness to neuroactive
agents show the quality of C-FBN-C as a novel type of animal neuron-
based biosensor.
4. Conclusion
Our previous publications have established a ﬁvemonth-long stable
C-FBN-C on a microelectrical array as a C-FBN-biosensor [10,11] and
characterized it pharmacologically by investigating its responsiveness
to Mg2+, TTX, and VER ([12], in review). This paper presents further
pharmacological characterization of the biosensor using AP5 and MUS.
The following conclusions can be made: 1) The C-FBN-biosensor re-
sponds to AP5 and MUS with a predictable dose-dependent inhibition
that is similar to the patterns of rodent counterparts with ED50 of
2.3 μM and 0.25 μM, respectively; 2) the C-FBN-biosensor shows
intrasensor reproducibility and can be sensitized when it is exposed to
the same agent again after a few days; 3) the C-FBN-biosensor demon-
strates long-term stability and reusability; and 4) the C-FBN-biosensor
may be used as an alternative biosensor to rodent counterparts in the
shared sensing domains of NMDA receptor and GABAA receptor.
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